Menana Elhallaoui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Menana Elhallaoui has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Abdelmoujoud Faris
LIMAS, Department of Chemical Sciences, Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez 30000, Morocco
3 shared publications - Asmaa Saleh
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
2 shared publications - Ibrahim M. Ibrahim
Biophysics Department, Faculty of Science, Cairo University, Giza 12613, Egypt
2 shared publications - Omkulthom Al Kamaly
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
2 shared publications - Adnane Aouidate
Laboratory of Organic Chemistry and Physical Chemistry, Team of Molecular Modeling, Materials and Environment, Faculty of Sciences, University Ibn Zohr, Agadir 80060, Morocco
1 shared publication - Jingjing Guo
Macao Polytechnic University
1 shared publication
Latest Publications
- Open Access
Computational 3D Modeling-Based Identification of Inhibitors Targeting Cysteine Covalent Bond Catalysts for JAK3 and CYP3A4 Enzymes in the Treatment of Rheumatoid Arthritis
This work aimed to find new inhibitors of the CYP3A4 and JAK3 enzymes, which are significant players in autoimmune diseases such as rheumatoid arthritis. Advanced computer-aided drug design techniques, such as pharmacophore and 3D-QSAR modeling, were used. Two strong 3D-QSAR models were created, and their predictive power was validated by the strong correlation (R2 values > 80%) between the predicted and experimental activity. With an ROC value of 0.9, a pharmacophore model grounded in the DHRRR hypothesis likewise demonstrated strong predictive ability. Eight possible inhibitors were found, and six new inhibitors were designed in silico using these computational models. The pharmacokinetic and safety characteristics of these candidates were thoroughly assessed. The possible interactions between the inhibitors and the target enzymes were made clear via molecular docking. Furthermore, MM/GBSA computations and molecular dynamics simulations offered insightful information about the stability of the binding between inhibitors and CYP3A4 or JAK3. Through the integration of various computational approaches, this study successfully identified potential inhibitor candidates for additional investigation and efficiently screened compounds. The findings contribute to our knowledge of enzyme–inhibitor interactions and may help us create more effective treatments for autoimmune conditions like rheumatoid arthritis.
Open AccessComputational 3D Modeling-Based Identification of Inhibitors Targeting Cysteine Covalent Bond Catalysts for JAK3 and CYP3A4 Enzymes in the Treatment of Rheumatoid Arthritis
This work aimed to find new inhibitors of the CYP3A4 and JAK3 enzymes, which are significant players in autoimmune diseases such as rheumatoid arthritis. Advanced computer-aided drug design techniques, such as pharmacophore and 3D-QSAR modeling, were used. Two strong 3D-QSAR models were created, and their predictive power was validated by the strong correlation (R2 values > 80%) between the predicted and experimental activity. With an ROC value of 0.9, a pharmacophore model grounded in the DHRRR hypothesis likewise demonstrated strong predictive ability. Eight possible inhibitors were found, and six new inhibitors were designed in silico using these computational models. The pharmacokinetic and safety characteristics of these candidates were thoroughly assessed. The possible interactions between the inhibitors and the target enzymes were made clear via molecular docking. Furthermore, MM/GBSA computations and molecular dynamics simulations offered insightful information about the stability of the binding between inhibitors and CYP3A4 or JAK3. Through the integration of various computational approaches, this study successfully identified potential inhibitor candidates for additional investigation and efficiently screened compounds. The findings contribute to our knowledge of enzyme–inhibitor interactions and may help us create more effective treatments for autoimmune conditions like rheumatoid arthritis.
- Open Access
Computer-Aided Drug Design of Novel Derivatives of 2-Amino-7,9-dihydro-8H-purin-8-one as Potent Pan-Janus JAK3 Inhibitors
Rheumatoid arthritis (RA) remains one of the most prevalent autoimmune diseases worldwide. Janus kinase 3 (JAK3) is an essential enzyme for treating autoimmune diseases, including RA. Molecular modeling techniques play a crucial role in the search for new drugs by reducing time delays. In this study, the 3D-QSAR approach is employed to predict new JAK3 inhibitors. Two robust models, both field-based with R2 = 0.93, R = 0.96, and Q2 = 87, and atom-based with R2 = 0.94, R = 0.97, and Q2 = 86, yielded good results by identifying groups that may readily direct their interaction. A reliable pharmacophore model, DHRRR1, was provided in this work to enable the clear characterization of chemical features, leading to the design of 13 inhibitors with their pIC50 values. The DHRRR1 model yielded a validation result with a ROC value of 0.87. Five promising inhibitors were selected for further study based on an ADMET analysis of their pharmacokinetic properties and covalent docking (CovDock). Compared to the FDA-approved drug tofacitinib, the pharmaceutical features, binding affinity and stability of the inhibitors were analyzed through CovDock, 300 ns molecular dynamics simulations, free energy binding calculations and ADMET predictions. The results show that the inhibitors have strong binding affinity, stability and favorable pharmaceutical properties. The newly predicted molecules, as JAK3 inhibitors for the treatment of RA, are promising candidates for use as drugs.
Open AccessComputer-Aided Drug Design of Novel Derivatives of 2-Amino-7,9-dihydro-8H-purin-8-one as Potent Pan-Janus JAK3 Inhibitors
Rheumatoid arthritis (RA) remains one of the most prevalent autoimmune diseases worldwide. Janus kinase 3 (JAK3) is an essential enzyme for treating autoimmune diseases, including RA. Molecular modeling techniques play a crucial role in the search for new drugs by reducing time delays. In this study, the 3D-QSAR approach is employed to predict new JAK3 inhibitors. Two robust models, both field-based with R2 = 0.93, R = 0.96, and Q2 = 87, and atom-based with R2 = 0.94, R = 0.97, and Q2 = 86, yielded good results by identifying groups that may readily direct their interaction. A reliable pharmacophore model, DHRRR1, was provided in this work to enable the clear characterization of chemical features, leading to the design of 13 inhibitors with their pIC50 values. The DHRRR1 model yielded a validation result with a ROC value of 0.87. Five promising inhibitors were selected for further study based on an ADMET analysis of their pharmacokinetic properties and covalent docking (CovDock). Compared to the FDA-approved drug tofacitinib, the pharmaceutical features, binding affinity and stability of the inhibitors were analyzed through CovDock, 300 ns molecular dynamics simulations, free energy binding calculations and ADMET predictions. The results show that the inhibitors have strong binding affinity, stability and favorable pharmaceutical properties. The newly predicted molecules, as JAK3 inhibitors for the treatment of RA, are promising candidates for use as drugs.
- Open Access
- 12 June 2023
- Published by Springer Nature in Research Square
In Silico Prediction of Potent Pan-Janus Kinase (JAK3) and CYP3A4 Inhibitors Using 2-Imidazopyridine and 2-Aminopyridone Purinones via Computer-Aided Drug Design
In this study, a 3D-QSAR analysis was performed using field-based and atom-based methods with a pharmacophore hypothesis approach to understand and identify the most important features that are associated with the inhibitory activity of JAK3/STAT and CYP3A4. The results for both field-based and atom-based methods showed good performance with R2 values of 0.93 and 0.94, R2 CV values of 0.51 and 0.47 and Q2 values of 0.87 and 0.86, respectively. Additionally, a pharmacophore DHRRR model was developed with a survival score of 5.88 to guide the design of new molecules. This study employed ADMET to predict the pharmacokinetic and pharmaceutical properties of candidate ligands, including solubility, permeability, and metabolic stability, which are critical for drug efficacy and pharmacokinetics. The present investigation aimed to explore the phenomenon of covalent binding between Janus Kinase (JAK3) and ligands, specifically targeting cysteine 909 (Cys909), a crucial player in the treatment of rheumatoid conditions. The findings of this study demonstrate that the establishment of covalent bonds between the ligands and Cys909 significantly enhances the inhibitory activity of JAK3/STAT, thus highlighting the potential therapeutic benefits in the context of rheumatoid treatment. Using molecular dynamics (MD) simulations and MM-GBSA calculations, potentially potent molecules were identified for selective JAK3/STAT inhibition. Finally, retrosynthesis was used to facilitate the synthetic pathway. These findings demonstrate the effectiveness of this computational approach in identifying promising new compounds for the development of JAK3/STAT drugs.
- 12 June 2023
- Published by Springer Nature in Research Square
Open AccessIn Silico Prediction of Potent Pan-Janus Kinase (JAK3) and CYP3A4 Inhibitors Using 2-Imidazopyridine and 2-Aminopyridone Purinones via Computer-Aided Drug Design
In this study, a 3D-QSAR analysis was performed using field-based and atom-based methods with a pharmacophore hypothesis approach to understand and identify the most important features that are associated with the inhibitory activity of JAK3/STAT and CYP3A4. The results for both field-based and atom-based methods showed good performance with R2 values of 0.93 and 0.94, R2 CV values of 0.51 and 0.47 and Q2 values of 0.87 and 0.86, respectively. Additionally, a pharmacophore DHRRR model was developed with a survival score of 5.88 to guide the design of new molecules. This study employed ADMET to predict the pharmacokinetic and pharmaceutical properties of candidate ligands, including solubility, permeability, and metabolic stability, which are critical for drug efficacy and pharmacokinetics. The present investigation aimed to explore the phenomenon of covalent binding between Janus Kinase (JAK3) and ligands, specifically targeting cysteine 909 (Cys909), a crucial player in the treatment of rheumatoid conditions. The findings of this study demonstrate that the establishment of covalent bonds between the ligands and Cys909 significantly enhances the inhibitory activity of JAK3/STAT, thus highlighting the potential therapeutic benefits in the context of rheumatoid treatment. Using molecular dynamics (MD) simulations and MM-GBSA calculations, potentially potent molecules were identified for selective JAK3/STAT inhibition. Finally, retrosynthesis was used to facilitate the synthetic pathway. These findings demonstrate the effectiveness of this computational approach in identifying promising new compounds for the development of JAK3/STAT drugs.